International Symposium of Tokyo University of Science, Translational Research (TR) Center —Frontiers in Developmental Strategy for Cancer Therapeutics—

Slides:

Advertisements

Similar presentations

2011 ASCO Genitourinary Cancers Symposium February 2011, Orlando

Advertisements

Reporting on Scientific Journal Articles Jeremy Moore, M.A. Senior Manager, Science Communications American Association for Cancer Research

SARC Developmental Therapeutics Committee Update Chand Khanna Open Science: Biology to Therapy” SARC Developmental Therapeutics Committee Update Chand.

Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”

Antibody and prodrug therapy of cancer

12 th KOREAN PEPTIDE-PROTEIN SOCIETY SYMPOSIUM Nov. 21, 2008 Kookmin University Organizing Committee Korean Peptide-Protein Society Department of Bio and.

Consortium for Interdisciplinary Studies on Science for Aging.

○ Area Yonsei Biomedical Science and Technology Initiative (YBSTI)

Fibroblast growth factor receptor (FGFR) gene family aberrations in cholangiocarcinoma Katsuyuki Miyabe, MD, PhD Lewis R. Roberts, MB ChB, PhD.

Penn Medicine Arthur H. Rubenstein, MBBCh October 26, ITMAT Symposium.

11 th KOREAN PEPTIDE SYMPOSIUM Nov. 30, 2007 Sogang University Dasan Hall Organizing Committee Korean Peptide Society Department of Chemistry Sogang University.

Bertrand Coiffier Professor, Department of Haematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France Prior posts at the Edouard-Herriot.

Foundation Doctors’ Academic Meeting Kathryn Adcock Wellcome Trust March 2011.

Hematopoietic Stem cell Transplantation – Present & Future Perspectives – International Commemorative Symposium of 500 Stem Cell Transplantations in Chonnam.

Special Seminar Series

Learning Health Systems: Working at the Intersection of Research, Operations and Big Data Welcome May 5, 2017.

Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.

OUHSC Vision/Initiatives for

14 November, 2016 Awareness on Diabetes World’s Diabetes Day

ISNM 11th International Symposium on Nanomedicine (ISNM2017) 2017

The 7th Biennial Meeting

Cancer Center: A Pathway to Collaborative Research and NCI Designation Mark Reeves, MD, PhD, Cancer Center Director 2016 Research Symposium, 10/21/16.

Systems Immunology on Healthy Aging and cancer

Call for participants and Posters !

Biography Assistant Vice Chancellor for Commercial Translation in the Health Sciences Visiting Associate Professor, Department of Biomedical Informatics.

Upfront Combination Therapy vs Step-Up Approach for PAH:

James Chih-Hsin Yang, Date: April 29-30, 2017

Yale SPORE in Skin Cancer

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Developing chemically modified, non-anticoagulant heparin derivatives as galectin-3-targeted novel anti-cancer/anti-metastasis drugs Professor Lu-Gang.

Monday, 23rd October, 2017, 5.00 p.m. c.t. Cluster of Excellence

SEMINAR 1. Title : Roles of microRNA in immune cell biology

Figure 5. Treatment of the checkpoint inhibitor related toxicity

University of Southern California

Sukhjeet bains Melissa Sylvester Wendy carpio Adriana monterroza

AN ATTEMPT TO REVERSE CANCER DRUG RESISTANCE

Graduate Institute of Institute of Pharmacology

The Institute for Molecular Diversity & Drug Design

From Bench to Clinical Applications: Money Talks

Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma Fred C. Lam, Michael B. Yaffe Cancer.

Welcome to Graduate School of Biomedical Sciences (GSBS)

سرطان الثدي Breast Cancer

Women scientists in breast cancer research:

Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell

KOREAN PEPTIDE-PROTEIN SOCIETY SYMPOSIUM

C. Allison Stewart, Lauren Averett Byers Cancer Cell

10th HIGH-TECH RESEARCH CENTER INTERNATIONAL SYMPOSIUM

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

CBTTC Fiscal Year 18 Strategic Objectives

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Advances in Psycho-oncology

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

C. Allison Stewart, Lauren Averett Byers Cancer Cell

Materials Chemistry and Physics

Essex University Science Conference

“Signaling Mechanisms Regulating CNS Myelination”

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature Manel Esteller, MD, PhD. Director, Josep Carreras Leukaemia Research.

Fertility and Sterility

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Prof. Jean-Marc Nabholtz, MD, MSc Chairman

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Institute of Pharmacology

Speakers and Session Chairs

The Role of TIPE2 Protein in Invasive Breast Carcinoma

Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.

KUMC Faculty Research Day

Presentation transcript:

International Symposium of Tokyo University of Science, Translational Research (TR) Center —Frontiers in Developmental Strategy for Cancer Therapeutics— Date：October 20 (Saturday), 2018 　10:30 - 19:00 Venue：Fujimi Bilding, Kagurazaka Campus, Tokyo University of Science, Japan 10:30 ~ 10:40 Opening Remarks 　　　　　　　 Soichiro Okamura, Vice-President, Tokyo University of Science 10:40 ~ 11:20 Invited Lecture 1 　 “Role of exosomal microRNAs in the biology of the Tumor Microenvironment ” Muller Fabbri., Ph.D., University of Hawaii 11:20 ~ 11:50 “Obesity and intestinal cancer development”　 Michihiro Mutoh, M.D., Ph.D., National Cancer Center, Japan 11:50 ~ 13:10 Lunch Break 13:10 ~ 13:40 “Design and Development of Nano and Cell Medicine for Cancer Therapy” Makiya Nishikawa, Ph.D., Tokyo University of Science 13:40 ~ 14:10 “Development of a novel therapeutic strategy for poor prognostic breast cancer by PARP1 degradation mechanism” Yoshikazu Higami, M.D., Ph.D., Tokyo University of Science 14:10 ~ 14:40 “Establishment of gastric cancer patient-derived xenografts (PDX) and cell lines” Takeshi Kuwata, M.D., Ph.D., National Cancer Center Hospital East, Japan 14:40 ~ 16:10 Coffee Break & Poster Session 16:10 ~ 16:50 Invited Lecture 2 “Azetidine-based small molecule inhibitors of STAT3 for treating triple negative breast cancer” James Turkson, Ph.D., University of Hawaii 16:50 ~ 17:20 “Development of New Methods for Cancer Theranostics in Interdisciplinary Collaboration of Tokyo University of Science” Shin Aoki, Ph.D., Tokyo University of Science 17:20 ~ 17:25 Closing Remarks 17:30 ~ 19:00 Banquet Supported by MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2014-2018 ＜Symposium Office＞ Prof. Takehisa Hanawa, TR Center, Research Institute for Science and Technology, Tokyo University of Science E-mail: y.kawano@rs.tus.ac.jp (Yayoi Kawano, Ph.D.)